製薬契約の開発および製造市場

出版:MarketsandMarkets

製薬契約の開発および製造市場:(医薬品、生物製剤、医薬品有効成分、錠剤、非経口、経口液剤、半固体)、エンドユーザー(ビッグファーマ、スモールファーマ、ジェネリックファーマ、CRO) – 2026年までの世界予測
Pharmaceutical Contract Development and Manufacturing Market (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma, CRO)-Global Forecast to 2026

出版 MarketsandMarkets
出版年月 2021年10月
ページ数 242
図表数 323
種別 英文調査報告書

レポート目次  お問合せ

The global pharmaceutical contract development and manufacturing market is projected to reach USD 171.3 billion by 2026 from USD 120.6 billion in 2021, at a CAGR of 7.3% during the forecast period. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.
“The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market, byend user, during the forecast period”
The pharmaceutical contract development and manufacturing market is segmented intobig pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, and other end users. The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market in 2021. This segment’s high growth can be attributed to the increasing number of emerging pharmaceutical companies that lack the in-house capabilities to manufacture and develop complex formulations and drug products.
“Biologics manufacturing services segment accounted for the highest CAGR”
Based on service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. In 2021, the biologics manufacturing services segment accounted for the highest growth rate. The major factor driving the growth of this segment is the growing demand for vaccines and biosimilars.
“Asia Pacific: The fastest-growing countryin thepharmaceutical contract development and manufacturing market”
Thepharmaceutical contract development and manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. This growth can be attributed to factors such as growth in the manufacturing sector, favorable government regulations, growing strategic expansions from leading companies, increasing emphasis on off-patent drugs, and the presence of a highly skilled workforce.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80%and Demand Side 20%
• By Designation: C-level – 25%, D-level – 20%, and Others – 55%
• By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
Lists of Companies Profiled in the Report:
• Thermo Fisher Scientific Inc. (US)
• Catalent, Inc. (US)
• Lonza Group Ltd. (Switzerland)
• Recipharm AB (Sweden)
• Siegfried Holding AG (Switzerland)
• WuXiAppTec (China)
• Samsung Biologics (South Korea)
• Boehringer Ingelheim International GmbH (Germany)
• Piramal Pharma Solutions (India)
• Vetter Pharma International GmbH (Germany)
• FAMAR Health Care Services (France)
• AbbVie Inc. (US)
• Aenova Group (Germany)
• Almac Group (UK)
• Evonik Industries AG (Germany)
• Cambrex Corporation (US)
• CordenPharma International (Germany)
• Albany Molecular Research Inc. (AMRI) (US)
• FUJIFILM Corporation (Japan)
• BioVectra (Canada)
Research Coverage:
This report provides a detailed picture of thepharmaceutical contract development and manufacturing market. It aims at estimating the size and future growth potential of the market across different segments,such as the service, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical contract development and manufacturing marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.


目次

1 INTRODUCTION 37
1.1 OBJECTIVES OF THE STUDY 37
1.2 MARKET DEFINITION 37
1.2.1 INCLUSIONS & EXCLUSIONS 37
1.3 MARKET SCOPE 38
1.3.1 MARKETS COVERED 38
1.3.2 YEARS CONSIDERED FOR THE STUDY 38
1.4 CURRENCY 39
1.5 LIMITATIONS 39
1.6 STAKEHOLDERS 39
1.7 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH APPROACH 41
2.1.1 SECONDARY DATA 41
2.1.2 PRIMARY DATA 42
FIGURE 1 BREAKDOWN OF PRIMARIES: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 42
2.2 MARKET DATA ESTIMATION & TRIANGULATION 43
FIGURE 2 DATA TRIANGULATION METHODOLOGY 43
2.3 MARKET ESTIMATION METHODOLOGY 44
FIGURE 3 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS-BASED ESTIMATION 44
FIGURE 4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SIZE (USD BILLION): FINAL MARKET SIZE 44
2.4 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 44
FIGURE 5 FINAL CAGR PROJECTIONS (2021−2026) 45
2.5 INSIGHTS FROM PRIMARIES 45
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 45
2.6 RESEARCH ASSUMPTIONS 46
3 EXECUTIVE SUMMARY 47
FIGURE 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE, BY SERVICE, 2020 47
FIGURE 8 BIOLOGICS MANUFACTURING SERVICES MARKET SHARE, BY TYPE, 2020 48
FIGURE 9 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021 VS. 2026 (USD BILLION) 48
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 49
4 PREMIUM INSIGHTS 50
4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET OVERVIEW 50
FIGURE 11 GROWING DEMAND FOR GENERICS IS ONE OF THE KEY FACTORS DRIVING MARKET GROWTH 50
4.2 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 51
FIGURE 12 PHARMACEUTICAL MANUFACTURING SERVICES TO COMMAND THE LARGEST SHARE OF THE EUROPEAN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 51
4.3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER 52
FIGURE 13 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 52
4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES BETWEEN 2021 & 2026 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 15 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS 54
5.2.1 DRIVERS 54
5.2.1.1 Patent expiry and increasing demand for generic drugs 54
5.2.1.2 Increasing investments in pharmaceutical R&D 55
FIGURE 16 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2020) 55
FIGURE 17 GLOBAL R&D SPENDING (2016–2020) 55
5.2.1.3 Investments in advanced manufacturing technologies by CDMOs 56
5.2.2 OPPORTUNITIES 57
5.2.2.1 Increasing demand for biological therapies 57
5.2.2.2 Growth in the nuclear medicine sector 57
5.2.2.3 Growing demand for cell and gene therapies 58
5.2.3 CHALLENGES 58
5.2.3.1 Introduction of serialization 58
5.2.4 TRENDS 59
5.2.4.1 Expansion in emerging countries 59
5.2.4.2 CDMO industry consolidation 59
TABLE 1 LIST OF ACQUISITIONS 59
5.3 VALUE CHAIN ANALYSIS 60
FIGURE 18 VALUE CHAIN ANALYSIS OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 60
5.4 ECOSYSTEM MARKET MAP 61
FIGURE 19 ECOSYSTEM OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 61
5.5 SUPPLY CHAIN 61
5.6 IMPACT OF THE COVID-19 PANDEMIC ON THE GROWTH OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 62
TABLE 2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 62
5.6.1 IMPACT ON THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 63
FIGURE 20 PRE-COVID VS. POST-COVID-19 SCENARIO, 2019–2021 63
5.7 REGULATORY ASSESSMENT 64
5.7.1 INTRODUCTION 64
5.8 PORTERS FIVE FORCES ANALYSIS 66
5.8.1 THREAT OF NEW ENTRANTS 66
5.8.2 THREAT OF SUBSTITUTES 67
5.8.3 BARGAINING POWER OF SUPPLIERS 67
5.8.4 BARGAINING POWER OF BUYERS 67
5.8.5 DEGREE OF COMPETITION 67
6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE 68
6.1 INTRODUCTION 69
TABLE 3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 69
TABLE 4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 69
6.2 PHARMACEUTICAL MANUFACTURING SERVICES 70
TABLE 5 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 70
TABLE 6 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 70
TABLE 7 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 71
TABLE 8 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 72
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES 72
6.2.1.1 Need to cut costs and ensure focus on core areas leads companies to outsource API manufacturing 72
TABLE 9 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 73
TABLE 10 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 74
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES 74
TABLE 11 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 75
TABLE 12 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 75
6.2.2.1 Parenteral/injectable manufacturing services 75
6.2.2.1.1 Need for high levels of expertise and growing drug development activities are driving the demand for contract manufacturing 75
TABLE 13 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2017–2020 (USD MILLION) 76
TABLE 14 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2021–2026 (USD MILLION) 77
6.2.2.2 Tablet manufacturing services 77
6.2.2.2.1 Shifting manufacturing requirements and the need to streamline production processes are driving market growth 77
TABLE 15 TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 78
TABLE 16 TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 79
6.2.2.3 Capsule manufacturing services 79
6.2.2.3.1 Growth in demand for capsule formulations has ensured growth opportunities for service providers 79
TABLE 17 CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 80
TABLE 18 CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 81
6.2.2.4 Oral liquid manufacturing services 81
6.2.2.4.1 Complexities involved in oral liquid manufacturing have prompted companies to opt for outsourcing 81
TABLE 19 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 82
TABLE 20 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 83
6.2.2.5 Semi-solid manufacturing services 83
6.2.2.5.1 Demand for specific manufacturing facilities and packaging to boost the outsourcing of semi-solids 83
TABLE 21 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 84
TABLE 22 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 85
6.2.2.6 Other formulations manufacturing services 85
TABLE 23 OTHER FORMULATIONS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 86
TABLE 24 OTHER FORMULATIONS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 87
6.3 DRUG DEVELOPMENT SERVICES 87
6.3.1 DRUG SUBSTANCE COMPLEXITY AND HIGH COSTS HAVE SUPPORTED THE OUTSOURCING OF DRUG DEVELOPMENT 87
TABLE 25 DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 88
TABLE 26 DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 89
6.4 BIOLOGICS MANUFACTURING SERVICES 89
TABLE 27 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 90
TABLE 28 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 90
6.4.1 BIOLOGICS API MANUFACTURING SERVICES 90
6.4.1.1 Market for biologics API manufacturing is still in the nascent phase 90
TABLE 29 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 91
TABLE 30 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 92
6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES 92
6.4.2.1 Increasing R&D costs and process complexity have prompted the shift toward contract manufacturing 92
TABLE 31 BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 93
TABLE 32 BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 94
7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER 95
7.1 INTRODUCTION 96
TABLE 33 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 96
TABLE 34 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 96
7.2 BIG PHARMACEUTICAL COMPANIES 97
7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPIES TO CONTRIBUTE TO THE GROWTH OF THIS MARKET 97
TABLE 35 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY,
2017–2020 (USD MILLION) 98
TABLE 36 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY,
2021–2026 (USD MILLION) 99
7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES 99
7.3.1 DEMAND IN BIOLOGICS DRUG DEVELOPMENT AND HIGH PRICING PRESSURE TO BOOST THE MARKET GROWTH 99
TABLE 37 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES,
BY COUNTRY, 2017–2020 (USD MILLION) 100
TABLE 38 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES,
BY COUNTRY, 2021–2026 (USD MILLION) 101
7.4 GENERIC PHARMACEUTICAL COMPANIES 101
7.4.1 GROWING DEMAND FOR GENERICS TO SUPPORT MARKET GROWTH 101
TABLE 39 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY,
2017–2020 (USD MILLION) 102
TABLE 40 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY,
2021–2026 (USD MILLION) 103
7.5 OTHER END USERS 103
TABLE 41 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2017–2020 (USD MILLION) 104
TABLE 42 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2026 (USD MILLION) 105
8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION 106
8.1 INTRODUCTION 107
FIGURE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT 107
TABLE 43 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2017–2020 (USD MILLION) 107
TABLE 44 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2021–2026 (USD MILLION) 108
8.2 EUROPE 108
FIGURE 22 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT 109
TABLE 45 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 110
TABLE 46 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 110
TABLE 47 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 111
TABLE 48 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 111
TABLE 49 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 111
TABLE 50 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 112
TABLE 51 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 112
TABLE 52 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 112
TABLE 53 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 113
TABLE 54 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 113
TABLE 55 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 113
TABLE 56 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 114
8.2.1 GERMANY 114
8.2.1.1 High healthcare expenditure and increased pharmaceutical production to support market growth 114
TABLE 57 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 115
TABLE 58 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 115
TABLE 59 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 115
TABLE 60 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 116
TABLE 61 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 116
TABLE 62 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 116
TABLE 63 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 117
TABLE 64 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 117
TABLE 65 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 117
TABLE 66 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 118
8.2.2 ITALY 118
8.2.2.1 Increasing focus on clinical research and the growing popularity of branded drugs are driving the demand for contract development and manufacturing 118
TABLE 67 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 119
TABLE 68 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 119
TABLE 69 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 119
TABLE 70 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 120
TABLE 71 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 120
TABLE 72 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 120
TABLE 73 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 121
TABLE 74 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 121
TABLE 75 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 121
TABLE 76 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 122
8.2.3 FRANCE 122
8.2.3.1 Presence of leading pharmaceutical companies to support market growth in France 122
TABLE 77 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 123
TABLE 78 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 123
TABLE 79 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 123
TABLE 80 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 124
TABLE 81 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2020 (USD MILLION) 124
TABLE 82 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 124
TABLE 83 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 125
TABLE 84 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 125
TABLE 85 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 125
TABLE 86 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 126
8.2.4 UK 126
8.2.4.1 Growth in the generics market and the rising cost of manufacturing parenteral formulations are driving market growth 126
TABLE 87 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 126
TABLE 88 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 127
TABLE 89 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 127
TABLE 90 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 127
TABLE 91 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 128
TABLE 92 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 128
TABLE 93 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 128
TABLE 94 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 129
TABLE 95 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 129
TABLE 96 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 129
8.2.5 SWITZERLAND 130
8.2.5.1 Large volume of pharmaceutical production and growing scope for generics to provide growth opportunities 130
TABLE 97 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 130
TABLE 98 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 130
TABLE 99 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 131
TABLE 100 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 131
TABLE 101 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 131
TABLE 102 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 132
TABLE 103 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 132
TABLE 104 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 132
TABLE 105 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 133
TABLE 106 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 133
8.2.6 SPAIN 133
8.2.6.1 Increase in biologics production to support market growth 133
TABLE 107 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 134
TABLE 108 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 134
TABLE 109 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 134
TABLE 110 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 135
TABLE 111 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 135
TABLE 112 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 135
TABLE 113 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 136
TABLE 114 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 136
TABLE 115 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 136
TABLE 116 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 137
8.2.7 POLAND 137
8.2.7.1 Rising public expenditure on healthcare to support the market growth in Poland 137
TABLE 117 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 137
TABLE 118 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 138
TABLE 119 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 138
TABLE 120 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 138
TABLE 121 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 139
TABLE 122 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 139
TABLE 123 POLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 139
TABLE 124 POLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 140
TABLE 125 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 140
TABLE 126 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 140
8.2.8 REST OF EUROPE 141
TABLE 127 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 141
TABLE 128 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 141
TABLE 129 ROE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 142
TABLE 130 ROE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 142
TABLE 131 ROE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 142
TABLE 132 ROE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 143
TABLE 133 ROE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 143
TABLE 134 ROE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 143
TABLE 135 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 144
TABLE 136 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 144
8.3 NORTH AMERICA 144
TABLE 137 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 145
TABLE 138 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 145
TABLE 139 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 145
TABLE 140 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 146
TABLE 141 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 146
TABLE 142 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 146
TABLE 143 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 147
TABLE 144 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 147
TABLE 145 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 147
TABLE 146 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 148
TABLE 147 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 148
TABLE 148 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 148
8.3.1 US 149
8.3.1.1 The US dominates the North American pharmaceutical contract development and manufacturing market 149
TABLE 149 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 149
TABLE 150 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 150
TABLE 151 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 150
TABLE 152 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 150
TABLE 153 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 151
TABLE 154 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 151
TABLE 155 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 151
TABLE 156 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 152
TABLE 157 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 152
TABLE 158 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 152
8.3.2 CANADA 153
8.3.2.1 Growth of the emerging markets and slowdown in new product approvals will hamper the market growth 153
TABLE 159 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 153
TABLE 160 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 153
TABLE 161 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 154
TABLE 162 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 154
TABLE 163 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 154
TABLE 164 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 155
TABLE 165 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 155
TABLE 166 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 155
TABLE 167 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 156
TABLE 168 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 156
8.4 ASIA PACIFIC 156
FIGURE 23 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT 157
TABLE 169 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 158
TABLE 170 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 158
TABLE 171 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 158
TABLE 172 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 159
TABLE 173 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 159
TABLE 174 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 159
TABLE 175 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 160
TABLE 176 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 160
TABLE 177 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 160
TABLE 178 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 161
TABLE 179 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 161
TABLE 180 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 161
8.4.1 CHINA 162
8.4.1.1 Favorable government regulations are fueling market growth in China 162
TABLE 181 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 162
TABLE 182 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 163
TABLE 183 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 163
TABLE 184 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 163
TABLE 185 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 164
TABLE 186 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 164
TABLE 187 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 164
TABLE 188 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 165
TABLE 189 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 165
TABLE 190 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 165
8.4.2 INDIA 166
8.4.2.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India 166
TABLE 191 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 166
TABLE 192 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 166
TABLE 193 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 167
TABLE 194 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 167
TABLE 195 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 167
TABLE 196 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 168
TABLE 197 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 168
TABLE 198 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 168
TABLE 199 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 169
TABLE 200 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 169
8.4.3 SOUTH KOREA 169
8.4.3.1 Government investments are a key contributor to market growth in South Korea 169
TABLE 201 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 170
TABLE 202 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 170
TABLE 203 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2020 (USD MILLION) 170
TABLE 204 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2021–2026 (USD MILLION) 171
TABLE 205 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 171
TABLE 206 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 171
TABLE 207 SOUTH KOREA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 172
TABLE 208 SOUTH KOREA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 172
8.4.4 JAPAN 172
8.4.4.1 Growing generics demand and government initiatives to drive the demand for contract manufacturing of drugs 172
TABLE 209 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 173
TABLE 210 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 173
TABLE 211 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 173
TABLE 212 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 174
TABLE 213 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 174
TABLE 214 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2021–2026 (USD MILLION) 174
TABLE 215 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 175
TABLE 216 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 175
TABLE 217 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 175
TABLE 218 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 176
8.4.5 REST OF ASIA PACIFIC 176
TABLE 219 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 177
TABLE 220 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 177
TABLE 221 ROAPAC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 177
TABLE 222 ROAPAC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 178
TABLE 223 ROAPAC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 178
TABLE 224 ROAPAC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2021–2026 (USD MILLION) 178
TABLE 225 ROAPAC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 179
TABLE 226 ROAPAC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 179
TABLE 227 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 179
TABLE 228 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 180
8.5 LATIN AMERICA 180
8.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM 180
TABLE 229 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 181
TABLE 230 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 181
TABLE 231 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 181
TABLE 232 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 182
TABLE 233 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 182
TABLE 234 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 182
TABLE 235 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 183
TABLE 236 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 183
TABLE 237 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 183
TABLE 238 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 184
8.6 MIDDLE EAST & AFRICA 184
8.6.1 GOVERNMENT SUPPORT TO BOOST LOCAL PRODUCTION IS EXPECTED TO OFFER GROWTH OPPORTUNITIES FOR CONTRACT MANUFACTURERS IN THE REGION 184
TABLE 239 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION) 185
TABLE 240 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION) 185
TABLE 241 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 185
TABLE 242 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 186
TABLE 243 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 186
TABLE 244 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 186
TABLE 245 MIDDLE EAST & AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION) 187
TABLE 246 MIDDLE EAST & AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION) 187
TABLE 247 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION) 187
TABLE 248 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION) 188
9 COMPETITIVE LANDSCAPE 189
9.1 OVERVIEW 189
9.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 189
9.3 MARKET SHARE ANALYSIS 190
FIGURE 25 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET RANK, BY KEY PLAYER, 2020 190
TABLE 249 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEGREE OF COMPETITION 191
9.4 COMPETITIVE LEADERSHIP MAPPING 192
9.4.1 STARS 193
9.4.2 EMERGING LEADERS 193
9.4.3 PERVASIVE PLAYERS 193
9.4.4 PARTICIPANTS 193
FIGURE 26 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT (2020) 194
9.5 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: START-UP/SME EVALUATION MATRIX, 2020 195
9.5.1 PROGRESSIVE COMPANIES 195
9.5.2 STARTING BLOCKS 195
9.5.3 RESPONSIVE COMPANIES 195
9.5.4 DYNAMIC COMPANIES 195
FIGURE 27 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: START-UP/SME EVALUATION MATRIX, 2020 196
9.6 COMPANY SERVICE FOOTPRINT 197
TABLE 250 SERVICE PORTFOLIO ANALYSIS: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 197
9.7 COMPANY GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 198
TABLE 251 GEOGRAPHIC REVENUE MIX: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET (2020) 198
9.8 COMPETITIVE SCENARIO 199
TABLE 252 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: SERVICE LAUNCHES, MAY 2019–OCTOBER 2020 199
TABLE 253 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEALS, MARCH 2019–AUGUST 2021 200
TABLE 254 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: OTHERS, MAY 2019–AUGUST 2021 201
10 COMPANY PROFILES 202
10.1 MAJOR PLAYERS 202
(Business overview, Services offered, Recent developments, and Right to win)*
10.1.1 LONZA GROUP 202
TABLE 255 LONZA GROUP: BUSINESS OVERVIEW 202
FIGURE 28 LONZA GROUP: COMPANY SNAPSHOT (2020) 202
TABLE 256 LONZA GROUP: SERVICES OFFERED 203
10.1.2 THERMO FISHER SCIENTIFIC INC. 207
TABLE 257 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 207
FIGURE 29 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020) 208
TABLE 258 THERMO FISHER SCIENTIFIC: SERVICES OFFERED 208
10.1.3 CATALENT 211
TABLE 259 CATALENT: BUSINESS OVERVIEW 211
FIGURE 30 CATALENT: COMPANY SNAPSHOT (2020) 212
TABLE 260 CATALENT: SERVICES OFFERED 212
10.1.4 RECIPHARM AB 218
TABLE 261 RECIPHARM AB: BUSINESS OVERVIEW 218
FIGURE 31 RECIPHARM AB: COMPANY SNAPSHOT 218
TABLE 262 RECIPHARM AB: SERVICES OFFERED 219
10.1.5 ABBVIE 221
TABLE 263 ABBVIE: BUSINESS OVERVIEW 221
FIGURE 32 ABBVIE: COMPANY SNAPSHOT (2020) 221
TABLE 264 ABBVIE: SERVICES OFFERED 222
10.1.6 SIEGFRIED HOLDING AG 223
TABLE 265 SIEGFRIED HOLDING AG: BUSINESS OVERVIEW 223
FIGURE 33 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2020) 223
TABLE 266 SIEGFRIED HOLDING AG: SERVICES OFFERED 223
10.1.7 EVONIK INDUSTRIES 225
TABLE 267 EVONIK INDUSTRIES: BUSINESS OVERVIEW 225
FIGURE 34 EVONIK INDUSTRIES: COMPANY SNAPSHOT (2020) 225
TABLE 268 EVONIK INDUSTRIES: SERVICES OFFERED 226
10.1.8 BOEHRINGER INGELHEIM 227
TABLE 269 BOEHRINGER INGELHEIM: BUSINESS OVERVIEW 227
FIGURE 35 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2020) 228
TABLE 270 BOEHRINGER INGELHEIM: SERVICES OFFERED 228
10.1.9 PIRAMAL PHARMA SOLUTIONS 230
TABLE 271 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW 230
FIGURE 36 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2020) 230
TABLE 272 PIRAMAL PHARMA SOLUTIONS: SERVICES OFFERED 231
10.1.10 SAMSUNG BIOLOGICS 232
TABLE 273 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW 232
FIGURE 37 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2020) 232
TABLE 274 SAMSUNG BIOLOGICS: SERVICES OFFERED 232
10.1.11 WUXI APPTEC (WUXI STA) 234
TABLE 275 WUXI APPTEC: BUSINESS OVERVIEW 234
FIGURE 38 WUXI APPTEC: COMPANY SNAPSHOT (2020) 234
TABLE 276 WUXI APPTEC: SERVICES OFFERED 235
10.1.12 FUJIFILM HEALTHCARE 236
TABLE 277 FUJIFILM HEALTHCARE: BUSINESS OVERVIEW 236
FIGURE 39 FUJIFILM HEALTHCARE: COMPANY SNAPSHOT (2020) 236
TABLE 278 FUJIFILM HEALTHCARE: SERVICES OFFERED 237
10.2 OTHER PLAYERS 238
10.2.1 VETTER PHARMA INTERNATIONAL 238
TABLE 279 VETTER PHARMA INTERNATIONAL: BUSINESS OVERVIEW 238
TABLE 280 VETTER PHARMA INTERNATIONAL: SERVICES OFFERED 238
10.2.2 FAMAR HEALTH CARE SERVICES 240
TABLE 281 FAMAR HEALTH CARE SERVICES: BUSINESS OVERVIEW 240
TABLE 282 FAMAR HEALTH CARE SERVICES: SERVICES OFFERED 240
10.2.3 AENOVA GROUP 242
TABLE 283 AENOVA GROUP: BUSINESS OVERVIEW 242
TABLE 284 AENOVA GROUP: SERVICES OFFERED 242
10.2.4 ALMAC GROUP 243
10.2.5 CAMBREX 243
10.2.6 CORDENPHARMA 244
10.2.7 BIOVECTRA 244
10.2.8 CURIA (FORMERLY ALBANY MOLECULAR RESEARCH) 245
*Details on Business overview, Services offered, Recent developments, and Right to win might not be captured in case of unlisted companies.
11 APPENDIX 246
11.1 DISCUSSION GUIDE 246
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 250
11.3 AVAILABLE CUSTOMIZATIONS 252
11.4 RELATED REPORTS 252
11.5 AUTHOR DETAILS 253


お問合せフォーム

    ※レポートのタイトルは自動で入ります。

    お名前(必須)

    会社名(必須)

    部署名

    メールアドレス(必須)

    電話番号

    当ウェブサイトを知った経由を教えてください。

    お問合せ区分(必須)

    お問合せ内容(必須)

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com